Preterm birth and low birth weight after in Utero exposure to antiretrovirals initiated during pregnancy in Yaoundé, Cameroon

PLoS ONE

Volumn 11, Issue 3, 2016, Pages

  Nlend, Anne Esther Njom ^a   Motazé, Annie Nga ^a   Tetang, Suzie Moyo ^a   Zeudja, Cécile ^a   Ngantcha, Marcus ^b   Tejiokem, Mathurin ^c  

^a Essos Hospital Center   (Cameroon)

^b Centre Pasteur of Cameroon ^*  (France)

^c CENTRE PASTEUR DU CAMEROUN   (Cameroon)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; CAMEROON; CD4 LYMPHOCYTE COUNT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DELIVERY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; MATERNAL AGE; MONOTHERAPY; PARITY; PREGNANCY; PREMATURE LABOR; PRENATAL DRUG EXPOSURE; PREVALENCE; RETROSPECTIVE STUDY; TREATMENT DURATION; VERTICAL TRANSMISSION; MOTHER; MULTIVARIATE ANALYSIS; PREMATURE BIRTH; PRENATAL EXPOSURE; YOUNG ADULT;

ADULT; ANTI-HIV AGENTS; CAMEROON; FEMALE; HUMANS; INFANT; INFANT, LOW BIRTH WEIGHT; MOTHERS; MULTIVARIATE ANALYSIS; PREGNANCY; PREMATURE BIRTH; PRENATAL EXPOSURE DELAYED EFFECTS; PREVALENCE; YOUNG ADULT;

EID: 84962091457     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0150565     Document Type: Article

References (32)

1. de Vincenzi I (2011) Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis 3: 171-80
2. UNAIDS (2011) Global plan towards the elimination of new HIVinfections among children by 2015 and keeping their mothers alive. Geneva: UNAIDS.
3. World Health Organization (2010) Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants. Recommandations for a public health approach. Geneva.
4. Ministry of Public Health (2009) Recommandations for use of antiretroviral drugs during pregnancy. Ministry of Public Health, Yaounde.
5. Njom Nlend A E, Ekobo C Same, Bitoungui M J, Ekani B Bagfegue, Tchokoteu P, Lyeb S, et al. (2012) Early outcomes of HIV exposed children in the first district-wide programme using extended regimens for the prevention of mother-to-child transmission of HIV, in Yaounde, Cameroon. J Trop Pediatr 4: 297-302
6. Senise JF, Castelo A, Martinez M (2011) Current treatment strategies, complications and considerations for the use of HIV antiretroviral therapy during pregnancy. AIDS Rev 4: 198-213
7. Thorne C, Patel D Newell M L (2004) Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe. Aids 17: 2337-9
8. Ekouevi DK, Coffie P A, Becquet R, Tonwe-Gold B, Horo A, Thiebaut R, et al. (2008) Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Cote d'Ivoire. Aids 14:1815-20
9. Nielsen-Saines K, Komarow L, Cu-Uvin S, Jourdain G, Klingman K L, Shapiro D E, et al. (2012) Infant outcomes after maternal antiretroviral exposure in resource-limited settings. Pediatrics 6: e1525-32
10. Olagbuji BN, Ezeanochie MC, Ande AB, Oboro VO (2010) Obstetric and perinatal outcome in HIV positive women receiving HAART in urban Nigeria. Arch Gynecol Obstet 6: 991-4
11. Dola CP, Khan R, DeNicola N, Amirgholami M, Benjamin T, Bhuiyan A, et al. (2011) Combination antiretroviral therapy with protease inhibitors in HIV-infected pregnancy. J Perinat Med 1:51-5
12. Watts D HL Mofenson M (2012) Antiretrovirals in pregnancy: a note of caution. J Infect Dis 11:1639-41
13. Alemu, Mazengia F, Yalew, Worku A, Fantahun Mesganaw (2013) Antiretroviral therapy and pregnancy outcomes in developing countries: A systematic review. International Journal 1: 31-43
14. Darak S, Darak T, Kulkarni S, Kulkarni V, Parchure R, Hutter I, et al. (2013) Effect of highly active antiretroviral treatment (HAART) during pregnancy on pregnancy outcomes: experiences from a PMTCT program in western India. AIDS Patient Care STDS 3:163-70
15. Sturt AS, Dokubo E K Sint TT (2010) Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women. Cochrane Database Syst Rev 3: CD008440 doi: 10.1002/14651858.CD008440 PMID: 20238370
16. Papp E, Mohammadi H, Loutfy M R, Yudin M H, Murphy KE, Walmsley S L, et al. (2015) HIV protease inhibitor use during pregnancy is associated with decreased progesterone levels, suggesting a potential mechanism contributing to fetal growth restriction. J Infect Dis 1:10-8
17. Patel K, Shapiro D E, Brogly S B, Livingston E G, Stek A M, Bardeguez A D, et al. (2010) Prenatal protease inhibitor use and risk of preterm birth among HIV-infected women initiating antiretroviral drugs during pregnancy. J Infect Dis 7:1035-44
18. Powis KM, Kitch D, Ogwu A, Hughes M D, Lockman S, Leidner J, et al. (2011) Increased risk of preterm delivery among HIV-infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancy. J Infect Dis 4: 506-14
19. Dos Reis H L, Kda S Araujo, Ribeiro LP, Da Rocha D R, Rosato D P, Passos M R, et al. (2015) Preterm birth and fetal growth restriction in HIV-infected Brazilian pregnant women. Rev Inst Med Trop Sao Paulo 2:111-20
20. Chen JY, Ribaudo H J, Souda S, Parekh N, Ogwu A, Lockman S, et al. (2012) Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana. J Infect Dis 11: 1695-705
21. Briand N, Mandelbrot L, LeChenadec J, Tubiana R, Teglas J P, Faye A, et al. (2009) No relation between in-utero exposure to HAART and intrauterine growth retardation. Aids 10:1235-43
22. Phiri K, Williams P L, Dugan KB, Fischer M A, Cooper WO, Seage G R 3rd, et al. (2015) Antiretroviral Therapy Use During Pregnancy and the Risk of Small for Gestational Age Birth in a Medicaid Population. Pediatr Infect Dis J 7: e169-75
23. Van derMerwe K, Hoffman R, Black V, Chersich M, Coovadia A, Rees H (2011) Birth outcomes in South African women receiving highly active antiretroviral therapy: a retrospective observational study. J Int AIDS Soc: 42 doi: 10.1186/1758-2652-14-42 PMID: 21843356
24. Young S, Murray K, Mwesigwa J, Natureeba P, Osterbauer B, Achan J, et al. (2012) Maternal nutritional status predicts adverse birth outcomes among HIV-infected rural Ugandan women receiving combination antiretroviral therapy. PLoS One 8: e41934
25. Browne JL, Schrier V J, Grobbee D E, Peters SA, Klipstein-Grobusch K (2015) HIV, Antiretroviral Therapy, and Hypertensive Disorders in Pregnancy: A Systematic Review and Meta-analysis. J Acquir Immune Defic Syndr 1:91-8
26. Aaron E, Bonacquisti A, Mathew L, Alleyne G, Bamford L P, Culhane J F (2012) Small-for-gestational-age births in pregnant women with HIV, due to severity of HIV disease, not antiretroviral therapy. Infect Dis Obstet Gynecol:
27. Ackerman WtJ Kwiek J (2013) Role of the placenta in adverse perinatal outcomes among HIV-1 seropositive women. J Nippon Med Sch 2: 90-4
28. Ndirangu J, Newell M L, Bland RM, Thorne C (2012) Maternal HIV infection associated with small-for-gestational age infants but not preterm births: evidence from rural South Africa. Hum Reprod 6:1846-56
29. Turner AN, Tabbah S, Mwapasa V, Rogerson S J, Meshnick S R, Ackerman W E t et al. (2013) Severity of maternal HIV-1 disease is associated with adverse birth outcomes in Malawian women: a cohort study. J Acquir Immune Defic Syndr 4: 392-9
30. Marazzi MC, Palombi L, Nielsen-Saines K, Haswell J, Zimba I, Magid N A, et al. (2011) Extended antenatal use of triple antiretroviral therapy for prevention of mother-to-child transmission of HIV-1 correlates with favorable pregnancy outcomes. Aids 13: 1611-8
31. Sibiude J, Warszawski J, Blanche S (2015) Tolerance of the newborn to antiretroviral drug exposure in utero. Expert Opin Drug Saf 5: 643-54
32. Tchetgen Tchetgen E J, Phiri K, Shapiro R (2015) A Simple Regression-based Approach to Account for Survival Bias in Birth Outcomes Research. Epidemiology 4: 473-80